Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy

Yi Pan, Carsten Brink, Marianne Knap, Azza A Khalil, Christa H Nyhus, Tine McCulloch, Bente Holm, Yi-Long Wu, Tine Schytte, Olfred Hansen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

PURPOSE: Esophagitis is common in patients treated with definitive radiotherapy for local-regional advanced non small cell lung cancer (NSCLC). The purpose of this study was to estimate the dose-effect relationship using clinical and dosimetric parameters in patients receiving intensity modulated radiotherapy (IMRT) and concomitant chemotherapy (CCT).

METHODS: Between 2009 and 2013, 117 patients with stages IIB-IIIB NSCLC were treated in a multicenter randomized phase II trial with 2 cycles of induction chemotherapy followed by IMRT and CCT. The esophagitis was prospectively scored using the Common Toxicity Criteria 3.0. Clinical and dosimetric variables were analyzed for the correlation with grade ⩾2 esophagitis through logistic regression.

RESULTS: Grade 2 esophagitis was experienced by 31 (27%). All models including gender, institution, a dosimetric parameter and a position parameter were significantly associated with esophagitis. The two models using the relative esophagus volume irradiated above 40Gy (V40, OR=2.18/10% volume) or the length of esophagus irradiated above 40Gy (L40, OR=4.03/5cm) were optimal. The upper part of esophagus was more sensitive and females experienced more toxicity than men.

CONCLUSION: V40 and L40 were most effective dosimetric predictors of grade ⩾2 esophagitis. The upper part of esophagus was more sensitive.

OriginalsprogEngelsk
TidsskriftRadiotherapy & Oncology
Vol/bind118
Udgave nummer3
Sider (fra-til)465–470
ISSN0167-8140
DOI
StatusUdgivet - 20. jan. 2016

Fingeraftryk

Esophagitis
Esophagus
dextran - saline drug combination
Intensity-Modulated Radiotherapy
Induction Chemotherapy
Logistic Models

Citer dette

Pan, Yi ; Brink, Carsten ; Knap, Marianne ; Khalil, Azza A ; Nyhus, Christa H ; McCulloch, Tine ; Holm, Bente ; Wu, Yi-Long ; Schytte, Tine ; Hansen, Olfred. / Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy. I: Radiotherapy & Oncology. 2016 ; Bind 118, Nr. 3. s. 465–470.
@article{323f4506ce22486aa12c90ff05934fbe,
title = "Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy",
abstract = "PURPOSE: Esophagitis is common in patients treated with definitive radiotherapy for local-regional advanced non small cell lung cancer (NSCLC). The purpose of this study was to estimate the dose-effect relationship using clinical and dosimetric parameters in patients receiving intensity modulated radiotherapy (IMRT) and concomitant chemotherapy (CCT).METHODS: Between 2009 and 2013, 117 patients with stages IIB-IIIB NSCLC were treated in a multicenter randomized phase II trial with 2 cycles of induction chemotherapy followed by IMRT and CCT. The esophagitis was prospectively scored using the Common Toxicity Criteria 3.0. Clinical and dosimetric variables were analyzed for the correlation with grade ⩾2 esophagitis through logistic regression.RESULTS: Grade 2 esophagitis was experienced by 31 (27{\%}). All models including gender, institution, a dosimetric parameter and a position parameter were significantly associated with esophagitis. The two models using the relative esophagus volume irradiated above 40Gy (V40, OR=2.18/10{\%} volume) or the length of esophagus irradiated above 40Gy (L40, OR=4.03/5cm) were optimal. The upper part of esophagus was more sensitive and females experienced more toxicity than men.CONCLUSION: V40 and L40 were most effective dosimetric predictors of grade ⩾2 esophagitis. The upper part of esophagus was more sensitive.",
author = "Yi Pan and Carsten Brink and Marianne Knap and Khalil, {Azza A} and Nyhus, {Christa H} and Tine McCulloch and Bente Holm and Yi-Long Wu and Tine Schytte and Olfred Hansen",
note = "Copyright {\circledC} 2016 Elsevier Ireland Ltd. All rights reserved.",
year = "2016",
month = "1",
day = "20",
doi = "10.1016/j.radonc.2016.01.007",
language = "English",
volume = "118",
pages = "465–470",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier",
number = "3",

}

Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy. / Pan, Yi; Brink, Carsten; Knap, Marianne; Khalil, Azza A; Nyhus, Christa H; McCulloch, Tine; Holm, Bente; Wu, Yi-Long; Schytte, Tine; Hansen, Olfred.

I: Radiotherapy & Oncology, Bind 118, Nr. 3, 20.01.2016, s. 465–470.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy

AU - Pan, Yi

AU - Brink, Carsten

AU - Knap, Marianne

AU - Khalil, Azza A

AU - Nyhus, Christa H

AU - McCulloch, Tine

AU - Holm, Bente

AU - Wu, Yi-Long

AU - Schytte, Tine

AU - Hansen, Olfred

N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

PY - 2016/1/20

Y1 - 2016/1/20

N2 - PURPOSE: Esophagitis is common in patients treated with definitive radiotherapy for local-regional advanced non small cell lung cancer (NSCLC). The purpose of this study was to estimate the dose-effect relationship using clinical and dosimetric parameters in patients receiving intensity modulated radiotherapy (IMRT) and concomitant chemotherapy (CCT).METHODS: Between 2009 and 2013, 117 patients with stages IIB-IIIB NSCLC were treated in a multicenter randomized phase II trial with 2 cycles of induction chemotherapy followed by IMRT and CCT. The esophagitis was prospectively scored using the Common Toxicity Criteria 3.0. Clinical and dosimetric variables were analyzed for the correlation with grade ⩾2 esophagitis through logistic regression.RESULTS: Grade 2 esophagitis was experienced by 31 (27%). All models including gender, institution, a dosimetric parameter and a position parameter were significantly associated with esophagitis. The two models using the relative esophagus volume irradiated above 40Gy (V40, OR=2.18/10% volume) or the length of esophagus irradiated above 40Gy (L40, OR=4.03/5cm) were optimal. The upper part of esophagus was more sensitive and females experienced more toxicity than men.CONCLUSION: V40 and L40 were most effective dosimetric predictors of grade ⩾2 esophagitis. The upper part of esophagus was more sensitive.

AB - PURPOSE: Esophagitis is common in patients treated with definitive radiotherapy for local-regional advanced non small cell lung cancer (NSCLC). The purpose of this study was to estimate the dose-effect relationship using clinical and dosimetric parameters in patients receiving intensity modulated radiotherapy (IMRT) and concomitant chemotherapy (CCT).METHODS: Between 2009 and 2013, 117 patients with stages IIB-IIIB NSCLC were treated in a multicenter randomized phase II trial with 2 cycles of induction chemotherapy followed by IMRT and CCT. The esophagitis was prospectively scored using the Common Toxicity Criteria 3.0. Clinical and dosimetric variables were analyzed for the correlation with grade ⩾2 esophagitis through logistic regression.RESULTS: Grade 2 esophagitis was experienced by 31 (27%). All models including gender, institution, a dosimetric parameter and a position parameter were significantly associated with esophagitis. The two models using the relative esophagus volume irradiated above 40Gy (V40, OR=2.18/10% volume) or the length of esophagus irradiated above 40Gy (L40, OR=4.03/5cm) were optimal. The upper part of esophagus was more sensitive and females experienced more toxicity than men.CONCLUSION: V40 and L40 were most effective dosimetric predictors of grade ⩾2 esophagitis. The upper part of esophagus was more sensitive.

U2 - 10.1016/j.radonc.2016.01.007

DO - 10.1016/j.radonc.2016.01.007

M3 - Journal article

C2 - 26803187

VL - 118

SP - 465

EP - 470

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

IS - 3

ER -